Delivery Order HHSN263201200024I-HHSN27200001

<p>The National Institute of Allergy and Infectious Diseases issued a delivery order to International AIDS Vaccine Initiative Inc. on September 19, 2017, with a ceiling value of $105,353.00 for product development plans to support HIV vaccine manufacturing efforts.</p> <p>Place of performance is New York, NY. The order is cost-plus-fixed-fee and was completed on September 19, 2018. No set-aside was used.</p>

<p>The National Institute of Allergy and Infectious Diseases issued a delivery order to International AIDS Vaccine Initiative Inc. on July 15, 2019, with a ceiling value of $3,170,861 for coordination and technical support in NIAID's process and analytical support program for HIV vaccine development.</p> <p>Place of performance is New York, NY. The order is priced on a cost-plus-fixed-fee basis with an ultimate completion date of July 14, 2020. No set-aside was used.</p>

<p>The National Institute of Allergy and Infectious Diseases issued a delivery order to International AIDS Vaccine Initiative Inc. on September 14, 2017, with a ceiling value of $432,452.00 for a feasibility assessment of HIV envelope protein antigens to de-obligate remaining 2017 funds.</p> <p>Place of performance is New York, NY. The order is priced on a cost-plus-fixed-fee basis with an ultimate completion date of October 31, 2018. No set-aside was used.</p>

This federal contract award, with a total ceiling value of $2,250,744.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to the International AIDS Vaccine Initiative (IAVI), a global non-profit organization focused on HIV vaccine development. The purpose of the contract is to develop an optimized Phase 1 current Good Manufacturing Practice (cGMP) manufacturing process for lipid nanoparticle (LNP) fabrication that enables covalent coupling of an HIV-1 envelope...

This is a cost-plus-fixed-fee delivery order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL). The $533,028.94 contract is for the development of HIV non-vaccine biomedical prevention products, including assessing product attributes, positioning, and messaging to drive adoption and use of new personal use products among young,...

The Department of the Army Medical Command awarded a $18 million Other Transaction Agreement to Janssen Vaccines &amp; Prevention B.V., doing business as JPC, to perform Phase 3 of the HPX3002/HVTN 706/MOSAICO pivotal efficacy study. The study will be conducted in the Netherlands to evaluate Janssen's investigational vaccine for the prevention of HIV-1 infection. As the Army's medical research agency, the Medical Command supports the development and testing of vaccines and therapies through...

This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to International AIDS Vaccine Initiative Inc. (IAVI), a non-profit organization. The $713,906.00 award supports the development of nanoparticle-based delivery systems for human immunodeficiency virus type 1 (HIV-1) biomolecules. The contract has a performance period ending on December 15, 2021 and utilizes a Cost...

This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services. The contract, valued at $3,731,476.00, is for the NIAID Preclinical Development Support program, specifically to support the production and testing of ADC6-HIV GP140 and ADC7-HIV GP140. The prime contractor is Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods that specializes in the...

<p>The National Institute of Allergy and Infectious Diseases issued a delivery order to International AIDS Vaccine Initiative Inc. on September 20, 2016, with a ceiling value of $1.572 million for purification of HIV envelope proteins using an immunoaffinity-based process.</p> <p>Work is performed in New York, NY. The order was priced on a cost-plus-fixed-fee basis and carried an ultimate completion date of June 15, 2020. The award included de-obligation of remaining FY 2017 funds.</p>

The National Institute of Allergy and Infectious Diseases issued a delivery order to International AIDS Vaccine Initiative Inc. on May 15, 2018, with a ceiling value of $55,936.00 under a Cost Plus Fixed Fee pricing structure. Place of performance is New York, NY. The ultimate completion date is May 14, 2019. The delivery order funds base task order work designated as OBRA-2, supporting vaccine development and related services within IAVI's research and development portfolio for infectious...